Top

Published in:

01-05-2012 | Thoracic Oncology

Pathologic Nonresponders after Neoadjuvant Chemoradiation for Esophageal Cancer Demonstrate no Survival Benefit Compared with Patients Treated with Primary Esophagectomy

Authors: George W. Dittrick, MD, Jill M Weber, MPH, Ravi Shridhar, MD, Sarah Hoffe, MD, Marcovalerio Melis, MD, Khaldoun Almhanna, MD, James Barthel, MD, James McLoughlin, Richard C. Karl, MD, Kenneth L. Meredith, MD

Published in: Annals of Surgical Oncology | Issue 5/2012

Abstract

Background

Neoadjuvant chemoradiation (NCRT) has become the preferred treatment for patients with locally advanced esophageal cancer. Survival often is correlated to degree of pathologic response; however, outcomes in patients who are found to be pathologic nonresponders (pNR) remain uninvestigated. This study was designed to evaluate survival in pNR to NCRT compared with patients treated with primary esophagectomy (PE).

Methods

Using our comprehensive esophageal cancer database, we identified patients treated with NCRT and deemed pNR along with patients who proceeded to PE. Clinical and pathologic data were compared using Fisher’s exact and χ², whereas Kaplan–Meier estimates were used for survival analysis.

Results

We identified 63 patients treated with NCRT and were found to have a pNR, and 81 patients who underwent PE. Disease-free (DFS) and overall survival (OS) were significantly decreased in the pNR group compared with those treated with PE (10 vs. 50 months (0–152), P < 0.001 and 13 vs. 50 months (0–152), P < 0.001, respectively). For patients with stage II disease, DFS and OS were similarly decreased in pathologic nonresponders (13 vs. 62 months (0–120), P < 0.001 and 31 vs. 62 months (0–120), P = 0.024, respectively). There were no differences in DFS or OS for patients with stage III disease (10 vs. 14 months (0–152), P = 0.29 and 10 vs. 19 months (0–152), P = 0.16, respectively).

Conclusions

Pathologic nonresponders to NCRT for esophageal cancer receive no benefit in DFS or OS compared with patients treated with PE. For patients with stage II disease, DFS and OS are, in fact, significantly decreased in the pNR.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.PubMedCrossRef

Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg. 1980;67(6):381–90.

Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical therapy of oesophageal carcinoma. Br J Surg. 1990;77(8):845–57.PubMedCrossRef

Wu PC, Posner MC, Wu PC, Posner MC. The role of surgery in the management of oesophageal cancer. Lancet Oncol. 2003;4(8):481–8.PubMedCrossRef

Reynolds JV, Muldoon C, Hollywood D, et al. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg. 2007;245(5):707–16.PubMedCrossRef

Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [see comment]. N Engl J Med. 2006;355(1):11–20.PubMedCrossRef

Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337(3):161–7.PubMedCrossRef

Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial [see comment]. Lancet Oncol. 2005;6(9):659–68.PubMedCrossRef

Gebski V, Burmeister B, Smithers BM, et al. (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis [see comment]. Lancet Oncol. 8(3): 226–34.PubMedCrossRef

10.

Jin J, Liao Z, Zhang Z, et al. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004;60(2):427–36.PubMedCrossRef

11.

Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer [see comment]. N Engl J Med. 1998;339(27):1979–84.PubMedCrossRef

12.

Naughton P, Walsh TN, Naughton P, Walsh TN. Preoperative chemo-radiotherapy improves 3-year survival in people with resectable oesophageal cancer. Cancer Treat Rev. 2004;30(1):141–4.PubMedCrossRef

13.

Pennathur A, Luketich JD, Landreneau RJ, et al. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. Ann Thorac Surg. 2008;85(6):1930–6; discussion 1936–7.

14.

Walsh TN, Grennell M, Mansoor S, et al. Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Dis Esophagus. 2002;15(2):121–4.PubMedCrossRef

15.

Rohatgi P, Swisher SG, Correa AM, et al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005;104(11):2365–72.PubMedCrossRef

16.

Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma [see comment]. J Clin Oncol. 2001;19(2):305–13.PubMed

17.

Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma [see comment] [erratum appears in N Engl J Med 1999;341(5):384]. N Engl J Med. 1996;335(7):462–7.PubMedCrossRef

18.

Meredith KL, Weber JM, Turaga KK, et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 2010;17(4):1159–67.PubMedCrossRef

19.

Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103(7):1347–55.PubMedCrossRef

20.

Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11): 2680–6.PubMedCrossRef

21.

Darnton SJ, Archer VR, Stocken DD, Mulholland PJ, Casson AG, Ferry DR. Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival [see comment]. J Clin Oncol. 2003;21(21):4009–15.PubMedCrossRef

22.

Luketich JD, Schauer PR, Meltzer CC, et al. Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg. 1997;64(3):765–9.PubMedCrossRef

23.

McLoughlin JM, Melis M, Siegel EM, et al. Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer? J Am Coll Surg. 2008;206(5):879–86; discussion 886–7.

24.

Aguirre ACR, Ramos-Font C, Portero RV, Cook GJR, Elvira JML, Tabares AR. 18F-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer systematic review of the literature. Ann Surg. 2009;250(2):247–54.CrossRef

25.

Sarkaria IS, Rizk NP, Bains MS, et al. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg. 2009;249(5):764–7.PubMedCrossRef

26.

Schneider PM, Metzger R, Schaefer H, et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg. 2008;248(6):902–8.PubMedCrossRef

27.

Schauer M, Janssen KP, Rimkus C, et al. Microarray-based response prediction in esophageal adenocarcinoma. Clin Cancer Res. 2010;16(1):330–7.PubMedCrossRef

28.

Maher SG, Gillham CM, Duggan SP, et al. Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg. 2009;250(5):729–37.PubMedCrossRef

Title: Pathologic Nonresponders after Neoadjuvant Chemoradiation for Esophageal Cancer Demonstrate no Survival Benefit Compared with Patients Treated with Primary Esophagectomy
Authors: George W. Dittrick, MD
Jill M Weber, MPH
Ravi Shridhar, MD
Sarah Hoffe, MD
Marcovalerio Melis, MD
Khaldoun Almhanna, MD
James Barthel, MD
James McLoughlin
Richard C. Karl, MD
Kenneth L. Meredith, MD
Publication date: 01-05-2012
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 5/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-011-2078-4

At a glance: The STEP trials

Springer Medicine

Pathologic Nonresponders after Neoadjuvant Chemoradiation for Esophageal Cancer Demonstrate no Survival Benefit Compared with Patients Treated with Primary Esophagectomy

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2012

DOK2 as a Marker of Poor Prognosis of Patients with Gastric Adenocarcinoma After Curative Resection

Combined Hepatocellular–Cholangiocarcinoma Had Poor Outcomes after Hepatectomy Regardless of Allen and Lisa Class or the Predominance of Intrahepatic Cholangiocarcinoma Cells within the Tumor

Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib

Comparison of Single-Port Laparoscopy, Standard Laparoscopy, and Robotic Surgery in Patients with Endometrial Cancer

A Population-Based Comparison of Adenocarcinoma of the Large and Small Intestine: Insights Into a Rare Disease

Cytoreductive Surgery with Selective Versus Complete Parietal Peritonectomy Followed by Hyperthermic Intraperitoneal Chemotherapy in Patients with Diffuse Malignant Peritoneal Mesothelioma: A Controlled Study